GlassScriptPhysician profile
John Silva
NPI 1154774164
$3,323.97
in general payments reported to CMS, 2019-2025
32 companies · $967 in 2025
The $967 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $1,060 · 2021: $587 · 2022: $34.49 · 2023: $43.02 · 2024: $404 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271 · Education: $113 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.10 |
| Education | $113.10 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $532.95 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Sanofi-Aventis U.S. LLC | $401.27 | 2019-2021 | |
| Novo Nordisk INC | $283.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $251.26 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.99 | 2020-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $176.84 | 2020-2025 | Rexulti |
| Abbvie INC. | $136.14 | 2021-2025 | |
| Allergan, INC. | $131.36 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $125.57 | 2019-2025 | Gardasil 9, M-M-R II, Rotateq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.71 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $96.89 | 2019-2020 | |
| Amarin Pharma, INC. | $90.18 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.45 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.47 | 2022-2025 | |
| Glaxosmithkline, LLC. | $77.57 | 2020-2025 | Shingrix, Trelegy Ellipta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $70.67 | 2020-2021 | |
| Abbott Laboratories | $66.34 | 2024-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Amgen INC. | $55.76 | 2022-2025 | Prolia, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $52.69 | 2020-2025 | Spravato |
| Cmp Pharma, INC. | $43.02 | 2023 | Tadliq, Carospir, Norliqva |
| E.R. Squibb & Sons, L.L.C. | $36.66 | 2019-2021 | |
| Exact Sciences Corporation | $34.60 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $28.07 | 2019-2020 | |
| Circassia INC. | $24.33 | 2019-2020 | |
| Grifols USA, LLC | $22.38 | 2020 | |
| Insulet Corporation | $21.55 | 2025 | Omnipod |
| Sumitomo Pharma America, INC. | $17.14 | 2024 | Gemtesa |
| Jazz Pharmaceuticals INC. | $15.52 | 2020 | |
| Radius Health, INC. | $13.80 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.50 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.30 | 2021 | |
| Cranial Technologies, INC | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.